심장 PoC 검사 기기 시장 : 제품 유형별, 최종 사용자별, 지역별(2026-2034년)

The global cardiac PoC testing devices market size reached USD 2.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.72% during 2026-2034. The growing prevalence of cardiovascular diseases due to excessive consumption of tobacco; rising need to detect brain natriuretic peptides, kinase, synthesizing troponin, and lactate dehydrogenase isoenzymes; and the thriving medical industry represent some of the key factors driving the market.

Cardiac point-of-care (PoC) testing devices are innovative and portable medical instruments designed for the rapid and accurate diagnosis of cardiac conditions. They are compact, user-friendly, and offer real-time results, enabling physicians to make prompt and informed decisions about patient care. They provide healthcare professionals with the ability to conduct diagnostic tests at the bedside of patients, eliminate the need for laboratory-based testing, and reduce turnaround times for critical cardiac assessments. They enhance the efficiency of clinical workflows by delivering accurate and reliable results within minutes. They assist in performing a variety of diagnostic tests, including cardiac biomarker analysis, coagulation monitoring, cholesterol profiling, and electrolyte measurement. They aid in obtaining immediate test results that facilitate more efficient patient triage, reduce overcrowding in emergency departments, and optimize resource allocation. As they minimize costs associated with sample transportation, lab personnel, and infrastructure by reducing the reliance on centralized laboratories, the demand for cardiac PoC testing devices is rising worldwide.

CARDIAC POC TESTING DEVICES MARKET TRENDS:

At present, the rising prevalence of cardiovascular diseases due to the excessive consumption of tobacco and alcohol represents one of the crucial factors bolstering the growth of the market. Moreover, there is an increase in the utilization of cardiac PoC testing devices to detect myocardial infarction and coronary syndromes around the world. This, along with the thriving medical industry, is supporting the growth of the market. In addition, the growing employment of these devices to identify brain natriuretic peptides, kinase, synthesizing troponin, and lactate dehydrogenase isoenzymes that are generated during heart failure is positively influencing the market. Besides this, key players are focusing on launching smartphone-based tests for cardiovascular diseases. They are also developing technologically advanced cardiac biomarker analyzers, which is bolstering the growth of the market. Additionally, there is a rise in the demand for cardiac analyzers, as they have software to provide an internal standard to account for membrane variability that is intrinsic to tests and integrated LCD displays for user convenience and visual clarity. This, coupled with the ability of analyzers to quantify the concentration of biomarkers in whole blood, serum, and plasma, which helps in clinical diagnosis, is impelling the growth of the market. Furthermore, the growing technological advancements in PoC testing devices are offering a favorable market outlook.

KEY MARKET SEGMENTATION:

Product Type Insights:

• Cardiac Markers Test
  • Cardiac Troponin (cTn) Test
  • Myoglobin Test
  • Creatine Kinase MB Isoenzyme (CK-MB) Test
  • Combinational Test Kits
  • Brain Natriuretic Peptide (BNP) Test
• Analyzers

End User Insights:

• Hospitals
• Diagnostic Laboratories
• Others

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cardiac PoC testing devices. Some of the factors driving the North America cardiac PoC testing devices market included the growing cardiovascular burden among the population, increasing healthcare expenditure, rising geriatric population, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global cardiac PoC testing devices market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, ACON Laboratories Inc., Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, LifeSign LLC, Nano-Ditech Corporation, Nexus-Dx Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global cardiac PoC testing devices market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global cardiac PoC testing devices market?
• What is the impact of each driver, restraint, and opportunity on the global cardiac PoC testing devices market?
• What are the key regional markets?
• Which countries represent the most attractive cardiac PoC testing devices market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the cardiac PoC testing devices market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the cardiac PoC testing devices market?
• What is the competitive structure of the global cardiac PoC testing devices market?
• Who are the key players/companies in the global cardiac PoC testing devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cardiac PoC Testing Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Cardiac Markers Test
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Cardiac Troponin (cTn) Test
    • 6.1.2.2 Myoglobin Test
    • 6.1.2.3 Creatine Kinase MB Isoenzyme (CK-MB) Test
    • 6.1.2.4 Combinational Test Kits
    • 6.1.2.5 Brain Natriuretic Peptide (BNP) Test
  • 6.1.3 Market Forecast
• 6.2 Analyzers
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Diagnostic Laboratories
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

• 9.1 Overview
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 ACON Laboratories Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Alfa Scientific Designs Inc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Bio-Rad Laboratories Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Danaher Corporation
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 F. Hoffmann-La Roche AG
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 LifeSign LLC
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 Nano-Ditech Corporation
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 Nexus-Dx Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio